Latest Conference Articles

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

September 17th 2021, 10:38pm

International Workshop on CLL

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Nivolumab/Ipilimumab Demonstrates Superior Likelihood of Long-Term Survival Vs Sunitinib in Advanced RCC

September 17th 2021, 10:24pm

ESMO Congress

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

Toripalimab/Chemo Combo Elicits Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma

September 17th 2021, 10:03pm

ESMO Congress

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib, Improves pCR, EFS in TNBC

September 17th 2021, 9:48pm

ESMO Congress

The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide significantly improved pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021, 9:45pm

ESMO Congress

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Frontline Nivolumab/Ipilimumab Maintains OS Benefit Across Subgroups in Unresectable Malignant Pleural Mesothelioma

September 17th 2021, 9:24pm

ESMO Congress

The frontline combination of nivolumab and ipilimumab continued to demonstrate improved overall survival across subgroups compared with standard chemotherapy at 3 years in patients with unresectable malignant pleural mesothelioma.

Sintilimab Improves OS in Advanced ESCC, G/GEJ

September 17th 2021, 9:03pm

ESMO Congress

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Erdafitinib plus Cetrelimab Exhibits Encouraging Efficacy in mUC

September 17th 2021, 8:02pm

ESMO Congress

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in in RCC

September 17th 2021, 7:20pm

ESMO Congress

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

VHL Mutated and VHL Wild Type Clear Cell RCC May Present Similar Clinical Characteristics

September 17th 2021, 2:36pm

ESMO Congress

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

Improved Communication Needed for Patients with A Subtype of Kidney Cancer

September 17th 2021, 2:20pm

ESMO Congress

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Frontline Immunotherapy Improves Survival in Advanced RCC, But Benefit to Be Determined for Favorable-Risk Subset

September 16th 2021, 10:18pm

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.

Brigatinib Maintains Superior PFS Benefit Over Crizotinib With High Intracranial Efficacy in ALK+ NSCLC

September 16th 2021, 9:50pm

ESMO Congress

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

Global Maximum-Tolerated Dose of Mobocertinib Found Tolerable in Japanese Patients With NSCLC

September 16th 2021, 9:43pm

ESMO Congress

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

Mobocertinib Shows Improved Responses Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC

September 16th 2021, 9:10pm

ESMO Congress

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer

September 16th 2021, 6:35pm

ESMO Congress

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021, 5:35pm

ESMO Congress

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC

September 16th 2021, 4:28pm

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Darolutamide Plus ADT Demonstrates Similar Safety Profile Vs ADT Alone in nmCRPC

September 16th 2021, 4:09pm

ESMO Congress

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC

September 16th 2021, 3:28pm

ESMO Congress

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.